Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

621 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials).
Tolleson TR, Newby LK, Harrington RA, Bhapkar MV, Verheugt FW, Berger PB, Moliterno DJ, White HD, Ohman EM, Van de Werf F, Topol EJ, Califf RM; SYMPHONY and the 2nd SYMPHONY Investigators. Tolleson TR, et al. Among authors: verheugt fw. Am J Cardiol. 2003 Aug 1;92(3):330-3. doi: 10.1016/s0002-9149(03)00641-6. Am J Cardiol. 2003. PMID: 12888148 Clinical Trial.
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.
Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators; Van De Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P, Barbash G, Betriu A, Binbrek AS, Califf R, Diaz R, Fanebust R, Fox K, Granger C, Heikkilä J, Husted S, Jansky P, Langer A, Lupi E, Maseri A, Meyer J, Mlczoch J, Mocceti D, Myburgh D, Oto A, Paolasso E, Pehrsson K, Seabra-Gomes R, Soares-Piegas L, Sùgrue D, Tendera M, Topol E, Toutouzas P, Vahanian A, Verheugt F, Wallentin L, White H. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, et al. Lancet. 1999 Aug 28;354(9180):716-22. doi: 10.1016/s0140-6736(99)07403-6. Lancet. 1999. PMID: 10475182 Clinical Trial.
Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA.
Van de Werf F, Barron HV, Armstrong PW, Granger CB, Berioli S, Barbash G, Pehrsson K, Verheugt FW, Meyer J, Betriu A, Califf RM, Li X, Fox NL; ASSENT-2 Investigators. Assessment of the Safety and Efficacy of a New Thrombolytic. Van de Werf F, et al. Among authors: verheugt fw. Eur Heart J. 2001 Dec;22(24):2253-61. doi: 10.1053/euhj.2001.2686. Eur Heart J. 2001. PMID: 11728145 Clinical Trial.
Early statin initiation and outcomes in patients with acute coronary syndromes.
Newby LK, Kristinsson A, Bhapkar MV, Aylward PE, Dimas AP, Klein WW, McGuire DK, Moliterno DJ, Verheugt FW, Weaver WD, Califf RM; SYMPHONY and 2nd SYMPHONY Investigators. Sibrafiban vs Aspirin to Yield Maximun Protection From Ischemic Heart Events Post-acute Coronary Syndromes. Newby LK, et al. Among authors: verheugt fw. JAMA. 2002 Jun 19;287(23):3087-95. doi: 10.1001/jama.287.23.3087. JAMA. 2002. PMID: 12069671
Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab.
Dubois CL, Belmans A, Granger CB, Armstrong PW, Wallentin L, Fioretti PM, López-Sendón JL, Verheugt FW, Meyer J, Van de Werf F; ASSENT-3 Investigators. Dubois CL, et al. Among authors: verheugt fw. J Am Coll Cardiol. 2003 Oct 1;42(7):1178-85. doi: 10.1016/s0735-1097(03)00917-3. J Am Coll Cardiol. 2003. PMID: 14522476 Free article. Clinical Trial.
Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation.
Newby LK, Bhapkar MV, White HD, Moliterno DJ, LaPointe NM, Kandzari DE, Verheugt FW, Kramer JM, Armstrong PW, Califf RM; SYMPHONY and 2nd SYMPHONY investigators. Newby LK, et al. Among authors: verheugt fw. J Thromb Thrombolysis. 2003 Dec;16(3):119-28. doi: 10.1023/B:THRO.0000024050.78728.35. J Thromb Thrombolysis. 2003. PMID: 15087598 Clinical Trial.
Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy.
Taher T, Fu Y, Wagner GS, Goodman SG, Fresco C, Granger CB, Wallentin L, van de Werf F, Verheugt F, Armstrong PW. Taher T, et al. J Am Coll Cardiol. 2004 Jul 7;44(1):38-43. doi: 10.1016/j.jacc.2004.03.041. J Am Coll Cardiol. 2004. PMID: 15234403 Free article. Clinical Trial.
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Blazing MA, de Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, DiBattiste PM, Palmisano J, Bilheimer DW, Snapinn SM, Ramsey KE, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM; 'A to Z' Investigators. Blazing MA, et al. Among authors: verheugt fw. JAMA. 2004 Jul 7;292(1):55-64. doi: 10.1001/jama.292.1.55. JAMA. 2004. PMID: 15238591 Clinical Trial.
Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3).
Curtis JP, Alexander JH, Huang Y, Wallentin L, Verheugt FW, Armstrong PW, Krumholz HM, Van de Werf F, Danays T, Cheeks M, Granger CB; ASSENT-2 and ASSENT-3 Investigators. Curtis JP, et al. Among authors: verheugt fw. Am J Cardiol. 2004 Aug 1;94(3):279-83. doi: 10.1016/j.amjcard.2004.04.019. Am J Cardiol. 2004. PMID: 15276088
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Gimona A, Matchaba P, Hawkey CJ, Chesebro JH; TARGET Study Group. Farkouh ME, et al. Among authors: verheugt fw. Lancet. 2004 Aug 21-27;364(9435):675-84. doi: 10.1016/S0140-6736(04)16894-3. Lancet. 2004. PMID: 15325832 Clinical Trial.
621 results